<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of autoinflammatory diseases (category VII inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of autoinflammatory diseases (category VII inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of autoinflammatory diseases (category VII inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12.5%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">T cells</td> <td class="subtitle1">B cells</td> <td class="subtitle1">Functional defects</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Type 1 interferonopathies</td> </tr> <tr> <td class="indent1">AD STING-associated vasculopathy, infantile onset (SAVI)</td> <td>Stimulator of interferon response cGAMP interactor 1 (<em>STING1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/612374" target="_blank">612374</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>STING activates both the NFkB and IRF3 transcription pathways to induce expression of IFN</td> <td>Skin vasculopathy, inflammatory lung disease, systemic autoinflammation and ICC, FCL</td> </tr> <tr> <td class="indent1">AR STING-associated vasculopathy, infantile onset (SAVI)</td> <td>Stimulator of interferon response cGAMP interactor 1 (<em>STING1</em>)</td> <td>AR GOF</td> <td><a href="https://www.omim.org/entry/615934" target="_blank">615934</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>STING activates both the NFkB and IRF3 transcription pathways to induce expression of IFN</td> <td>Failure to thrive, early-onset rash, fever, dyspnea, interstitial lung disease/pneumonitis, polyarthritis, autoantibodies, increased inflammatory markers, IFN gene signature; phenocopy of SAVI due to AD GOF <em>STING1</em></td> </tr> <tr> <td class="indent1">ADA2 deficiency</td> <td>Adenosine deaminase 2 (<em>ADA2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607575" target="_blank">607575</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>ADAs deactivate extracellular adenosine and terminate signaling through adenosine receptors</td> <td>Childhood-onset polyarteritis nodosa, early-onset recurrent ischemic stroke and fever, some patients develop hypogammaglobulinemia</td> </tr> <tr> <td class="indent1">TREX1 deficiency, AGS1</td> <td>Three-prime repair exonuclease 1 (<em>TREX1</em>)</td> <td>AR and AD</td> <td><a href="https://www.omim.org/entry/606609" target="_blank">606609</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Intracellular accumulation of abnormal ssDNA species leading to increased type I IFN production</td> <td>Classical AGS, SLE, FCL</td> </tr> <tr> <td class="indent1">RNASEH2B deficiency, AGS2</td> <td>Ribonuclease H2 subunit B (<em>RNASEH2B</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610326" target="_blank">610326</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Intracellular accumulation of abnormal RNA-DNA hybrid species leading to increased type I IFN production</td> <td>Classical AGS, spastic paraparesis</td> </tr> <tr> <td class="indent1">RNASEH2C deficiency, AGS3</td> <td>Ribonuclease H2 subunit C (<em>RNASEH2C</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610330" target="_blank">610330</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Intracellular accumulation of abnormal RNA-DNA hybrid species leading to increased type I IFN production</td> <td>Classical AGS</td> </tr> <tr> <td class="indent1">RNASEH2A deficiency, AGS4</td> <td>Ribonuclease H2 subunit A (<em>RNASEH2A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606034" target="_blank">606034</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Intracellular accumulation of abnormal RNA-DNA hybrid species leading to increased type I IFN production</td> <td>Classical AGS</td> </tr> <tr> <td class="indent1">SAMHD1 deficiency, AGS5</td> <td>SAM and HD domain-containing deoxynucleoside triphosphate (<em>SAMHD1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606754" target="_blank">606754</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Controls dNTPs in the cytosol, failure of which leads to increased type I IFN production</td> <td>Classical AGS, FCL</td> </tr> <tr> <td class="indent1">ADAR1 deficiency, AGS6</td> <td>Adenosine deaminase RNA specific (<em>ADAR</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/146920" target="_blank">146920</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Catalyzes the deamination of adenosine to inosine in dsRNA substrates, failure of which leads to increased type I IFN production</td> <td>Classical AGS, BSN, spastic paraparesis</td> </tr> <tr> <td class="indent1">AGS7</td> <td>Interferon induced with helicase C domain 1 (<em>IFIH1</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/615846" target="_blank">615846</a></td> <td>Not assessed</td> <td>Not assessed</td> <td><em>IFIH1</em> gene encodes a cytoplasmic viral RNA receptor that activates type 1 IFN signaling through the MAVS adaptor molecule</td> <td>Classical AGS, SLE, spastic paraparesis, SMS</td> </tr> <tr> <td class="indent1">DNAse II deficiency</td> <td>Deoxyribonuclease 2, lysosomal (<em>DNASE2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/126350" target="_blank">126350</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>DNAse II degrades and eliminates DNA; loss of DNAse II activity induces type I IFN signaling</td> <td>AGS</td> </tr> <tr> <td class="indent1">LSM11 deficiency</td> <td>LSM11, U7 small nuclear RNA associated (<em>LSM11</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619486" target="_blank">619486</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Increased IFN signaling in fibroblasts</td> <td>AGS, type 1 IFN-opathy</td> </tr> <tr> <td class="indent1">RNU7-1 deficiency</td> <td>RNA, U7 small nuclear 1 (<em>RNU7-1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619487" target="_blank">619487</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Increased IFN signaling in fibroblasts</td> <td>AGS, type 1 IFN-opathy</td> </tr> <tr> <td class="indent1">Pediatric SLE due to DNASE1L3 deficiency</td> <td>Deoxyribonuclease 1-like 3 (<em>DNASE1L3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614420" target="_blank">614420</a></td> <td> </td> <td> </td> <td>DNASE1L3 is an endonuclease that degrades extracellular DNA; DNASE1L3 deficiency decreased clearance of apoptotic cells</td> <td>Very-early-onset SLE, reduced complement levels, autoantibodies (dsDNA, ANCA), lupus nephritis, hypocomplementemic urticaria vasculitis syndrome</td> </tr> <tr> <td class="indent1">Spondyloenchondrodysplasia with immune dysregulation (SPENCD)</td> <td>Acid phosphatase 5, tartrate resistant (<em>ACP5</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/171640" target="_blank">171640</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Upregulation of IFN through a mechanism possibly relating to pDCs</td> <td>Short stature, spastic paraparesis, ICC, SLE, thrombocytopenia and autoimmune hemolytic anemia, possibly recurrent bacterial and viral infections</td> </tr> <tr> <td class="indent1">X-linked reticulate pigmentary disorder</td> <td>DNA polymerase alpha 1, catalytic subunit (<em>POLA1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/301220" target="_blank">301220</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>POLA1 is required for synthesis of cytosolic RNA:DNA; its deficiency leads to increased production of type I IFN</td> <td>Hyperpigmentation, characteristic facies, lung and GI involvement</td> </tr> <tr> <td class="indent1">USP18 deficiency</td> <td>Ubiquitin-specific peptidase 18 (<em>USP18</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607057" target="_blank">607057</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Defective negative regulation of ISG15 leading to increased IFN</td> <td>TORCH-like syndrome</td> </tr> <tr> <td class="indent1">OAS1 deficiency</td> <td>2'-5'-oligoadenylate synthetase 1 (<em>OAS1</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/164350" target="_blank">164350</a></td> <td> </td> <td>Low</td> <td>Increased IFN from recognition of RNA</td> <td>Pulmonary alveolar proteinosis, skin rash</td> </tr> <tr> <td class="indent1">CDC42 deficiency</td> <td>Cell division cycle 42 (<em>CDC42</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616737" target="_blank">616737</a></td> <td>Normal/decreased</td> <td>Normal/decreased</td> <td>Increased serum levels of IL-1, IL-18, IFN-gamma, ferritin, sCD25, CRP, etc; mutation affects actin function; decreased NK cell cytotoxicity</td> <td>Neonatal onset: pancytopenia, fever, rash, hepatosplenomegaly, multisystemic inflammation, myelofibrosis/proliferation, HLH, enterocolitis; recurrent GI tract/upper respiratory tract infections; neurodevelopmental delay, failure to thrive</td> </tr> <tr> <td class="indent1">STAT2 R148 LOF/regulation</td> <td>Signal transducer and activator of transcription 2 (<em>STAT2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/616636" target="_blank">616636</a></td> <td>Increased</td> <td>Normal</td> <td>Patient cells hypersensitive to IFN-alpha; GOF for induction of the late (not early) response to type 1 IFNs due to impaired interaction of mutant STAT2 with USP18, a negative regulator of type 1 IFN responses</td> <td>Severe fatal early-onset autoinflammation, elevated serum IFN-alpha, IL-6, TNF-alpha; phenocopy of USP18 deficiency</td> </tr> <tr> <td class="indent1">ATAD3A deficiency</td> <td>ATPase family AAA domain-containing 3A (<em>ATAD3A</em>)</td> <td>AD and AR</td> <td><a href="https://www.omim.org/entry/617183" target="_blank">617183</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Increased ISG expression; increased serum type 1 IFNs</td> <td>Predominantly neurologic defects (developmental delay, spasticity)</td> </tr> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1" colspan="2">Affected cells</td> <td class="subtitle1">Functional defects</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Defects affecting the inflammasome</td> </tr> <tr> <td class="indent1" rowspan="2">Familial Mediterranean fever</td> <td rowspan="2">MEFV innate immunity regulator, pyrin (<em>MEFV</em>)</td> <td>AR LOF</td> <td><a href="https://www.omim.org/entry/249100" target="_blank">249100</a></td> <td colspan="2">Mature granulocytes, cytokine-activated monocytes</td> <td>Increased inflammasome-mediated induction of IL-1-beta</td> <td>Recurrent fever, serositis and inflammation responsive to colchicine, predisposes to vasculitis and IBD</td> </tr> <tr> <td>AD</td> <td><a href="https://www.omim.org/entry/134610" target="_blank">134610</a></td> <td colspan="2">Mature granulocytes, cytokine-activated monocytes</td> <td>Usually M694del variant</td> <td>Recurrent fever, serositis and inflammation responsive to colchicine, predisposes to vasculitis and IBD</td> </tr> <tr> <td class="indent1">Mevalonate kinase deficiency (hyper-IgD syndrome)</td> <td>Mevalonate kinase (<em>MVK</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/260920" target="_blank">260920</a></td> <td colspan="2">Somatic and hematopoietic</td> <td>Affecting cholesterol synthesis, pathogenesis of disease unclear</td> <td>Periodic fever and leukocytosis with high IgD levels</td> </tr> <tr> <td class="indent1">Muckle-Wells syndrome</td> <td>NLR family pyrin domain containing 3 (<em>NLRP3</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/191900" target="_blank">191900</a></td> <td colspan="2">PMNs, monocytes</td> <td>Defect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processing</td> <td>Urticaria, SNHL, amyloidosis</td> </tr> <tr> <td class="indent1">Familial cold autoinflammatory syndrome 1</td> <td>NLR family pyrin domain containing 3 (<em>NLRP3</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/120100" target="_blank">120100</a></td> <td colspan="2">PMNs, monocytes</td> <td>Defect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processing</td> <td>Nonpruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure</td> </tr> <tr> <td class="indent1">Neonatal-onset multisystem inflammatory disease (NOMID) or chronic infantile neurologic cutaneous and articular syndrome (CINCA)</td> <td>NLR family pyrin domain containing 3 (<em>NLRP3</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/607115" target="_blank">607115</a></td> <td colspan="2">PMNs, chondrocytes</td> <td>Defect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processing</td> <td>Neonatal-onset rash, chronic meningitis, arthropathy with fever and inflammation</td> </tr> <tr> <td class="indent1">Familial cold autoinflammatory syndrome 2</td> <td>NLR family pyrin domain containing 12 (<em>NLRP12</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/611762" target="_blank">611762</a></td> <td colspan="2">PMNs, monocytes</td> <td>Defect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processing</td> <td>Nonpruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure</td> </tr> <tr> <td class="indent1">NLRC4-MAS</td> <td>NLR family CARD domain containing 4 (<em>NLRC4</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/616050" target="_blank">616050</a></td> <td colspan="2">PMNs, monocytes, macrophages</td> <td>GOF mutation in <em>NLRC4</em> results in elevated secretion of IL-1-beta and IL-18 as well as macrophage activation</td> <td>Severe enterocolitis and MAS</td> </tr> <tr> <td class="indent1">Familial cold autoinflammatory syndrome 4</td> <td>NLR family CARD domain containing 4 (<em>NLRC4</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/616115" target="_blank">616115</a></td> <td colspan="2">PMNs, monocytes, macrophages</td> <td>GOF mutation in <em>NLRC4</em> results in elevated secretion of IL-1-beta and IL-18 as well as macrophage activation</td> <td>Severe enterocolitis and MAS</td> </tr> <tr> <td class="indent1">PLC-gamma-2-associated antibody deficiency and immune dysregulation (PLAID)</td> <td>Phospholipase C gamma 2 (<em>PLCG2</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/614878" target="_blank">614878</a></td> <td colspan="2">B cells, NK cells, mast cells</td> <td>Mutations activate IL-1 pathways</td> <td>Cold urticaria, hypogammaglobulinemia, impaired humoral immunity, autoinflammation</td> </tr> <tr> <td class="indent1">Familial cold autoinflammatory syndrome 3 or APLAID (c2120A&gt;C)</td> <td>Phospholipase C gamma 2 (<em>PLCG2</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/614468" target="_blank">614468</a></td> <td colspan="2">B cells, NK cells, mast cells</td> <td>Mutations activate IL-1 pathways</td> <td>Cold urticaria, hypogammaglobulinemia, impaired humoral immunity, autoinflammation</td> </tr> <tr> <td class="indent1">NLRP1 deficiency</td> <td>NLR family pyrin domain containing 1 (<em>NLRP1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617388" target="_blank">617388</a></td> <td colspan="2">Leukocytes</td> <td>Systemic elevation of IL-18 and caspase 1, suggesting involvement of NLRP1 inflammasome</td> <td>Dyskeratosis, autoimmunity and arthritis</td> </tr> <tr> <td class="indent1">NLRP1 GOF</td> <td>NLR family pyrin domain containing 1 (<em>NLRP1</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/615225" target="_blank">615225</a></td> <td colspan="2">Keratinocytes</td> <td>Increased IL-1-beta</td> <td>Palmoplantar carcinoma, corneal scarring, recurrent respiratory papillomatosis</td> </tr> <tr> <td class="indent1">RIPK1 deficiency</td> <td>Receptor-interacting serine/threonine kinase 1 (<em>RIPK1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/618852" target="_blank">618852</a></td> <td colspan="2"> </td> <td>Increased inflammatory markers and proinflammatory cytokines/gene signature</td> <td>Autoinflammatory disorder: regular/prolonged fevers, lymphadenopathy, splenomegaly/hepatomegaly, ulcers, arthralgia, GI features</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Noninflammasome-related conditions</td> </tr> <tr> <td class="indent1">TNF receptor-associated periodic syndrome (TRAPS)</td> <td>TNF receptor superfamily member 1A (<em>TNFRSF1A</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/142680" target="_blank">142680</a></td> <td colspan="2">PMNs, monocytes</td> <td>Mutations of 55-kD TNF receptor leading to intracellular receptor retention or diminished soluble cytokine receptor available to bind TNF</td> <td>Recurrent fever, serositis, rash, and ocular or joint inflammation</td> </tr> <tr> <td class="indent1">Pyogenic sterile arthritis, pyoderma gangrenosum, acne (PAPA) syndrome, hyperzincemia and hypercalprotectinemia</td> <td>Proline-serine-threonine phosphatase-interacting protein 1 (<em>PSTPIP1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/604416" target="_blank">604416</a></td> <td colspan="2">Hematopoietic tissues, upregulated in activated T cells</td> <td>Disordered actin reorganization leading to compromised physiologic signaling during inflammatory response</td> <td>Destructive arthritis, inflammatory skin rash, myositis</td> </tr> <tr> <td class="indent1">Blau syndrome</td> <td>Nucleotide-binding oligomerization domain-containing 2 (<em>NOD2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/186580" target="_blank">186580</a></td> <td colspan="2">Monocytes</td> <td>Mutations in nucleotide binding site of CARD15, possibly disrupting interactions with lipopolysaccharides and NFkB signaling</td> <td>Uveitis, granulomatous synovitis, camptodactyly, rash and cranial neuropathies, 30% develop Crohn colitis</td> </tr> <tr> <td class="indent1">ADAM17 deficiency</td> <td>ADAM metallopeptidase domain 17 (<em>ADAM17</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614328" target="_blank">614328</a></td> <td colspan="2">Leukocytes, epithelial cells</td> <td>Defective TNF-alpha production</td> <td>Early-onset diarrhea and skin lesions</td> </tr> <tr> <td class="indent1">Chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia (Majeed syndrome)</td> <td>Lipin 2 (<em>LPIN2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/609628" target="_blank">609628</a></td> <td colspan="2">Neutrophils, bone marrow cells</td> <td>Undefined</td> <td>Chronic recurrent multifocal osteomyelitis, transfusion-dependent anemia, cutaneous inflammatory disorders</td> </tr> <tr> <td class="indent1">Deficiency of the IL-1 receptor antagonist (DIRA)</td> <td>Interleukin 1 receptor antagonist (<em>IL1RN</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/612852" target="_blank">612852</a></td> <td colspan="2">PMNs, monocytes</td> <td>Mutations in <em>IL1RN</em> allow unopposed action of IL-1</td> <td>Neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis</td> </tr> <tr> <td class="indent1">Deficiency of IL-36 receptor antagonist (DITRA)</td> <td>Interleukin 36 receptor antagonist (<em>IL36RN</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614204" target="_blank">614204</a></td> <td colspan="2">Keratinocytes, leukocytes</td> <td>Mutations in <em>IL36RN</em> lead to increased IL-8 production</td> <td>Pustular psoriasis</td> </tr> <tr> <td class="indent1">SLC29A3 mutation</td> <td>Solute carrier family 29 member 3 (<em>SLC29A3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602782" target="_blank">602782</a></td> <td colspan="2">Leukocytes, bone cells</td> <td> </td> <td>Hyperpigmentation, hypertrichosis, histiocytosis-lymphadenopathy plus syndrome</td> </tr> <tr> <td class="indent1">CARD14-mediated psoriasis (CAMPS)</td> <td>Caspase recruitment domain family member 14 (<em>CARD14</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/602723" target="_blank">602723</a></td> <td colspan="2">Mainly keratinocytes</td> <td>Mutations in <em>CARD14</em> activate the NFkB pathway and production of Il-8</td> <td>Psoriasis</td> </tr> <tr> <td class="indent1">Cherubism</td> <td>SH3 domain binding protein 2 (<em>SH3BP2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/118400" target="_blank">118400</a></td> <td colspan="2">Stroma cells, bone cells</td> <td>Hyperactive macrophage and increased NFkB</td> <td>Bone degeneration in jaws</td> </tr> <tr> <td class="indent1" rowspan="2">Chronic atypical neutrophilic dermatitis with lipodystrophy (CANDLE)</td> <td>Proteasome 20S subunit beta 8 (<em>PSMB8</em>)*</td> <td>AR and AD</td> <td><a href="https://www.omim.org/entry/256040" target="_blank">256040</a></td> <td colspan="2">Keratinocytes, B cell adipose cells</td> <td>Mutations cause increased IFN signaling through an undefined mechanism</td> <td>Contractures, panniculitis, ICC, fevers</td> </tr> <tr> <td>Proteasome assembly chaperone 2 (<em>PSMG2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/609702" target="_blank">609702</a></td> <td colspan="2">Lymphocytes</td> <td>Mutations cause increased IFN signaling through an undefined mechanism</td> <td>Panniculitis, lipodystrophy, autoimmune hemolytic anemia</td> </tr> <tr> <td class="indent1">COPA defect</td> <td>COPI coat complex subunit alpha (<em>COPA</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/601924" target="_blank">601924</a></td> <td colspan="2">PMNs and tissue-specific cells</td> <td>Defective intracellular transport via the coat protein complex I (COPI)</td> <td>Autoimmune inflammatory arthritis and interstitial lung disease with Th17 dysregulation and autoantibody production</td> </tr> <tr> <td class="indent1">Otulipenia/OTULIN-related autoinflammatory syndrome  (ORAS)</td> <td>OTU deubiquitinase with linear linkage specificity (<em>OTULIN</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615712" target="_blank">615712</a></td> <td colspan="2">Leukocytes</td> <td>Increased LUBAC induction of NFkB activation leading to high proinflammatory cytokine levels</td> <td>Fever, diarrhea, dermatitis</td> </tr> <tr> <td class="indent1">A20 deficiency</td> <td>TNF-alpha-induced protein 3 (<em>TNFAIP3</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616744" target="_blank">616744</a></td> <td colspan="2">Lymphocytes</td> <td>Defective inhibition of NFkB signaling pathway</td> <td>Arthralgia, mucosal ulcers, ocular inflammation</td> </tr> <tr> <td class="indent1">AP1S3 deficiency</td> <td>Adaptor-related protein complex 1 subunit sigma 3 (<em>AP1S3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615781" target="_blank">615781</a></td> <td colspan="2">Keratinocytes</td> <td>Disrupted TLR3 translocation</td> <td>Pustular psoriasis</td> </tr> <tr> <td class="indent1">ALPI deficiency</td> <td>Alkaline phosphatase, intestinal (<em>ALPI</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/171740" target="_blank">171740</a></td> <td colspan="2">Intestinal epithelial cells</td> <td>Deficient inhibition of LPS in intestine</td> <td>IBD</td> </tr> <tr> <td class="indent1">TRIM22 deficiency</td> <td>Tripartite motif containing 22 (<em>TRIM22</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606559" target="_blank">606559</a></td> <td colspan="2">Macrophages, intestinal epithelial cells</td> <td>Granulomatous colitis</td> <td>IBD</td> </tr> <tr> <td class="indent1">T cell lymphoma subcutaneous panniculitis-like (TIM3 deficiency)</td> <td>Hepatitis A virus cellular receptor 2 (<em>HAVCR2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618398" target="_blank">618398</a></td> <td colspan="2">Leukocytes</td> <td>Increased inflammasome activity due to defective checkpoint signaling</td> <td>Panniculitis, HLH, polyclonal cutaneous T cell infiltrates or T cell lymphoma</td> </tr> <tr> <td class="indent1">C2orf69 deficiency</td> <td>Chromosome 2 open reading frame 69 (<em>C2orf69</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619423" target="_blank">619423</a></td> <td colspan="2"> </td> <td> </td> <td>Early-onset severe autoinflammation disorder, often fatal; global developmental delay with recurrent seizures, muscle weakness, liver dysfunction</td> </tr> <tr> <td class="indent1">NCKAP1L deficiency</td> <td>NCK-associated protein 1-like (<em>NCKAP1L</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618982" target="_blank">618982</a></td> <td colspan="2">Lymphocytes</td> <td>Hyperinflammation and cytokine overproduction (increased Th1), decreased T cell proliferation, cytoskeletal defects</td> <td>Recurrent upper respiratory tract infection, skin rashes/abscesses/atopy, ulcers, lymphoproliferation/lymphadenopathy, hyperinflammation, anti-dsDNA antibodies, fever, failure to thrive</td> </tr> <tr> <td class="indent1">SYK GOF</td> <td>Spleen-associated tyrosine kinase (<em>SYK</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/619381" target="_blank">619381</a></td> <td colspan="2">Lymphocytes</td> <td>Increased SYK phosphorylation, enhanced downstream signaling</td> <td>Recurrent infections, multiorgan inflammation/inflammatory disease (gut, skin, CNS, lung, liver), B cell lymphoma (2 patients)</td> </tr> <tr> <td class="indent1">HCK GOF</td> <td>HCK proto-oncogene, Src family tyrosine kinase (<em>HCK</em>)</td> <td>AD GOF</td> <td> </td> <td colspan="2"> </td> <td>Increased kinase activity of HCK mutant in vitro, increased production of inflammatory cytokines (IL-1-beta, IL-8, IL-8, TNF-alpha), ROS</td> <td>Cutaneous vasculitis, inflammatory leukocyte infiltration of the lungs (pulmonary fibrosis) and skin, anemia, hepatosplenomegaly</td> </tr> <tr> <td class="indent1">PSMB9 GOF</td> <td>Proteasome 20S subunit beta 9 (<em>PSMB9</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/617591" target="_blank">617591</a></td> <td colspan="2">Mild pancytopenia, leukocytes</td> <td>Elevated levels of inflammatory cytokines (IL-6, IL-18, IP-10, IFN-alpha), liver enzymes in blood and CSF (IFN-alpha), hyperactivation of IFN-alpha, pSTAT1, reduced proteasome activities</td> <td>Severe autoinflammatory phenotype (neonatal-onset fever, skin rash, myositis, severe pulmonary hypertension, basal ganglia calcification), periodic inflammatory exacerbation, immunodeficiency; partial phenocopy of PRAAS</td> </tr> <tr> <td class="indent1">IKBKG (NEMO exon 5 deletion)</td> <td>Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (<em>IKBKG</em>)</td> <td>XL</td> <td> </td> <td colspan="2">Leukocytes</td> <td>Mutant NEMO lacked exon 5, failed to bind TBK1 and stabilized IKKi, increasing type 1 IFN production</td> <td>Fever, skin, rash, systemic autoinflammation, infections, CNS involvement, panniculitis, uveitis, hepatosplenomegaly, ectodermal dysplasia</td> </tr> <tr> <td class="indent1">TBK1 deficiency</td> <td>TANK-binding kinase 1 (<em>TBK1</em>)</td> <td>AR</td> <td> </td> <td colspan="2">Leukocytes</td> <td>Autoinflammation driven by TNF-induced RIPK1-dependent cell death</td> <td>Chronic systemic autoinflammation (polyarthritis, vasculitis, rash), delayed neurocognitive development</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of disorders in table: 56.</div><div class="graphic_footnotes"><p>IUIS: International Union of Immunological Societies; 
        AD: autosomal dominant; 
        NFkB: nuclear factor kappa B; 
        IRF: interferon regulatory factor; 
        IFN: interferon; 
        ICC: intracranial calcification; 
        FCL: familial chilblain lupus; 
        AR: autosomal recessive; 
        GOF: gain of function; 
        AGS: Aicardi-Goutières syndrome; 
        ssDNA: single-stranded deoxyribonucleic acid; 
        SLE: systemic lupus erythematosus; 
        RNA: ribonucleic acid; 
        dNTP: deoxynucleoside triphosphate; 
        dsRNA: double-stranded RNA; 
        BSN: bilateral striatal necrosis; 
        MAVS: mitochondrial antiviral-signaling protein; 
        SMS: Singleton-Merten syndrome; 
        dsDNA: double-stranded DNA; 
        ANCA: antineutrophil cytoplasmic antibody; 
        pDC: plasmacytoid dendritic cell; 
        XL: X linked; 
        GI: gastrointestinal; 
        ISG: interferon-stimulated gene; 
        TORCH: toxoplasmosis, other (syphilis), rubella, cytomegalovirus, herpes simplex virus; 
        IL: interleukin; 
        CRP: C-reactive protein; 
        NK: natural killer; 
        HLH: hemophagocytic lymphohistiocytosis; 
        LOF: loss of function; 
        TNF: tumor necrosis factor; 
        IBD: inflammatory bowel disease; 
        IgD: immunoglobulin D; 
        PMN: polymorphonuclear neutrophil;
        SNHL: sensorineural hearing loss; 
        MAS: macrophage activation syndrome; 
        CARD15: caspase recruitment domain family, member 15; 
        Th17: T helper type 17; 
        LUBAC: linear ubiquitin chain assembly complex; 
        TLR: toll-like receptor; 
        LPS: lipopolysaccharide; 
        TIM3: T cell immunoglobulin mucin family member 3; 
        Th1: T helper type 1; 
        CNS: central nervous system; 
        ROS: reactive oxygen species; 
        IP-10: IFN-gamma inducible protein 10kDa; 
        CSF: cerebrospinal fluid; 
        NEMO: NFkB essential modulator; 
        TBK1: TANK-binding kinase 1; 
        IKKi: I-kappa-B kinase epsilon; 
        RIPK1: receptor-interacting serine/threonine kinase 1.</p>
<p class="extra_spacing_top">* Variants in proteasome 20S subunit beta 4 (<em>PSMB4</em>), proteasome 20S subunit beta 9 (<em>PSMB9</em>), proteasome 20S subunit alpha 3 (<em>PSMA3</em>), and proteasome maturation protein (<em>POMP</em>) have been proposed to cause a similar CANDLE phenotype in compound heterozygous monogenic (<em>PSMB4</em>), digenic (<em>PSMA3</em>/<em>PSMB8</em>), <em>PSMB4</em>/<em>PSMB8</em>), and AD monogenic (<em>POMP</em>) models.<sup>[1]</sup></p></div><div class="graphic_reference">Reference:
    <ol>
<li>Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015; 125:4196.</li>
</ol>
<p class="extra_spacing_top">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright © 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</p></div><div id="graphicVersion">Graphic 140047 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
